Mark Laughlin

1.6k total citations · 1 hit paper
12 papers, 1.2k citations indexed

About

Mark Laughlin is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Mark Laughlin has authored 12 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hepatology, 5 papers in Infectious Diseases and 5 papers in Epidemiology. Recurrent topics in Mark Laughlin's work include Hepatitis C virus research (7 papers), HIV/AIDS drug development and treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Mark Laughlin is often cited by papers focused on Hepatitis C virus research (7 papers), HIV/AIDS drug development and treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Mark Laughlin collaborates with scholars based in United States, France and United Kingdom. Mark Laughlin's co-authors include Karen L. Lindsay, Eugene R. Schiff, Tobias Heintges, Janice K. Albrecht, Stuart C. Gordon, Mitchell L. Shiffman, Zachary Goodman, Ruji Yao, Christian Trépo and John C. Hoefs and has published in prestigious journals such as The Lancet, Hepatology and The Journal of Infectious Diseases.

In The Last Decade

Mark Laughlin

12 papers receiving 1.1k citations

Hit Papers

A Randomized, Double–Blind Trial Comparing Pegylated Inte... 2001 2026 2009 2017 2001 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
    2001 507 citations Karen L. Lindsay, Christian Trépo et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Laughlin United States 9 893 813 131 130 85 12 1.2k
M. Baldi Italy 13 635 0.7× 683 0.8× 63 0.5× 79 0.6× 62 0.7× 39 940
Nasser Semmo Switzerland 19 830 0.9× 672 0.8× 113 0.9× 144 1.1× 110 1.3× 61 1.2k
P. J. Grob Switzerland 13 410 0.5× 460 0.6× 130 1.0× 86 0.7× 78 0.9× 42 970
Robert Lagier United States 9 344 0.4× 337 0.4× 55 0.4× 86 0.7× 65 0.8× 23 554
Lai My Taiwan 13 704 0.8× 730 0.9× 39 0.3× 45 0.3× 52 0.6× 32 909
G. Grossi Italy 13 534 0.6× 561 0.7× 15 0.1× 90 0.7× 88 1.0× 28 880
Florian van Bömmel Germany 24 2.2k 2.4× 2.2k 2.7× 37 0.3× 350 2.7× 84 1.0× 97 2.5k
Xiaoxi Lu China 13 123 0.1× 194 0.2× 78 0.6× 39 0.3× 228 2.7× 33 585
Selma Rebus United Kingdom 10 243 0.3× 294 0.4× 26 0.2× 187 1.4× 169 2.0× 18 671
Benedetta Campana Switzerland 8 234 0.3× 244 0.3× 30 0.2× 38 0.3× 67 0.8× 13 499

Countries citing papers authored by Mark Laughlin

Since Specialization
Citations

This map shows the geographic impact of Mark Laughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laughlin more than expected).

Fields of papers citing papers by Mark Laughlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Laughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laughlin. The network helps show where Mark Laughlin may publish in the future.

Co-authorship network of co-authors of Mark Laughlin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Laughlin. A scholar is included among the top collaborators of Mark Laughlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Laughlin. Mark Laughlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Asselah, Tarik, Laurent Essioux, Patrick Marcellin, et al.. (2010). 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN. Journal of Hepatology. 52. S456–S456. 14 indexed citations
3.
4.
Caldwell, Katharine E., et al.. (2008). Fetal alcohol spectrum disorder-associated depression: Evidence for reductions in the levels of brain-derived neurotrophic factor in a mouse model. Pharmacology Biochemistry and Behavior. 90(4). 614–624. 91 indexed citations
5.
Silva, Marcelo, Jorge Luis Poo, Frank Wagner, et al.. (2006). A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology. 45(2). 204–213. 87 indexed citations
6.
Lurie, Yael, Régine Rouzier‐Panis, G. Webster, et al.. (2005). Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 3(6). 610–615. 5 indexed citations
7.
González‐Peralta, Regino P., Déirdre Kelly, Barbara Haber, et al.. (2005). Interferon Alfa-2b in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Children: Efficacy, Safety, and Pharmacokinetics *. Hepatology. 42(5). 1010–1018. 85 indexed citations
8.
Laughlin, Mark, et al.. (2002). Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic‐pharmacodynamic models. Clinical Pharmacology & Therapeutics. 72(4). 349–361. 45 indexed citations
9.
Lindsay, Karen L., Christian Trépo, Tobias Heintges, et al.. (2001). A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C. Hepatology. 34(2). 395–403. 507 indexed citations breakdown →
10.
Émilie, Dominique, Marianne Burgard, Caroline Lascoux‐Combe, et al.. (2001). Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNα: results from the Primoferon A (ANRS 086) Study. AIDS. 15(11). 1435–1437. 48 indexed citations
11.
Lushbaugh, William B., et al.. (1994). A Double-Blind Placebo-Controlled Trial of Single-Dose Intravaginal versus Single-Dose Oral Metronidazole in the Treatment of Trichomonal Vaginitis. The Journal of Infectious Diseases. 170(1). 242–246. 25 indexed citations
12.
Lushbaugh, William B., et al.. (1994). A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF ORAL VERSUS VAGINAL METRONIDAZOLE FOR THE TREATMENT OF TRICHOMONAL VAGINITIS. 170. 242–246. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Baldi Breakdown of academic impact, for papers by Nasser Semmo Breakdown of academic impact, for papers by P. J. Grob Breakdown of academic impact, for papers by Robert Lagier Breakdown of academic impact, for papers by Lai My Breakdown of academic impact, for papers by G. Grossi Breakdown of academic impact, for papers by Florian van Bömmel Breakdown of academic impact, for papers by Xiaoxi Lu Breakdown of academic impact, for papers by Selma Rebus Breakdown of academic impact, for papers by Benedetta Campana
Rankless by CCL
2026